Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for ...

June 28 (Reuters) - The U.S. Justice Department closed a criminal probe into Abbott Laboratories over its handling of a baby ...

Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products, and its portfolio boasts dozens of patented devices that generate consistent ...

Shares of Abbott Laboratories (ABT) gained on Wednesday after Baird initiated coverage with an Outperform rating and a $121 price target, citing a stable growth trajectory for the MedTech company ...

For Q2, according to Seeking Alpha, analysts are expecting normalized EPS of $1.28, GAAP EPS of $0.97, and $12.52bn of ...

Abbott trades near its 52-week low of $99.06, well below the $137.13 52-week high. Q1 2026 earnings arrive in two days. Abbott shares have declined 19.22% year-to-date and 6.79% over the past month.

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.